Treatment Free Remission (<scp>TFR</scp>) in Chronic Phase‐Chronic Myeloid Leukemia (<scp>CP</scp>‐<scp>CML</scp>): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecular Relapse
TFR is feasible in real-world settings. BASE-TFR score may help to better identify candidates for TKI discontinuation in real-life settings.
Authors
- Claudia Ielo (ORCID: https://orcid.org/0009-0003-2295-7321)
- Alessandro Laganà (ORCID: https://orcid.org/0009-0005-9432-224X)
- Daniela Diverio (ORCID: https://orcid.org/0000-0003-0494-7165)
- Maurizio Martelli (ORCID: https://orcid.org/0000-0003-1007-0339)
- Emilia Scalzulli
- Ida Carmosino
- Maria Laura Bisegna
- Massimo Breccia (ORCID: https://orcid.org/0000-0003-1163-6162)
Institutions
- Policlinico Umberto I (IT)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1111/ejh.70006
- Citations
- 3
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31